Drug intelligence / Profile preview

ATC-0001

Development stage: Preclinical
Lead developer: Amtix Bio
Modality: Small Molecules

Overview

ATC-0001 is a chemical drug under preclinical development by Amtix Bio Co., Ltd. It is being investigated primarily for the treatment of infectious diseases, with a specific focus on aspergillosis. The detailed mechanism of action and molecular target have not been disclosed in public sources as of June 2025. The drug has not yet entered clinical trials and remains in the preclinical research phase[1][5].

Other names: ATC-0001ATC0001ATC 0001

Beyond the preview

Go deeper on ATC-0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATC-0001.

Explore the full profile